3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
7
Phase 2
4
Phase 1
3
Phase 1/2
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
4
Conditions
Breast Neoplasms
106
Carcinoma, Intraductal, Noninfiltrating
6
Neoplasms
4
Neoplasm Metastasis
3
Breast Neoplasms, Male
3
Breast Diseases
3
Breast Carcinoma In Situ
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Sexual Dysfunction, Physiological
1
Seizures
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Inflammatory Breast Neoplasms
1
Hypogonadism
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Epilepsy
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasm Female
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
Anastrozole
×
Clear all
NCT04075604
2022-08-10
CheckMate 7A8
Bristol-Myers Squibb
Phase 2
Completed
23 enrolled
20 charts
NCT00274469
2019-09-06
FIRST
AstraZeneca
Phase 2
Completed
205 enrolled
13 charts
NCT01151215
2014-07-25
MINT
AstraZeneca
Phase 2
Terminated
482 enrolled
10 charts
NCT00357110
2010-12-21
@FAME
AstraZeneca
Phase 2
Completed
13 enrolled
7 charts